MQR GPW Periodic report · PAP Biznes
Pure Biologics SA (MQR) · Q1 2026 results
Share price: 1.40 zł · 2026-11-10
Results Q1 2026 vs Q1 2025 · year over year · published 29 May 2026 and 15 May 2025
Net loss widened year on year. The report's language is unchanged.
Only a basic analysis is available for this company at the moment.
1 · Numbers
Loss widened
Net income vs Q1 2025
Net income -2.2M vs -1.3M
2 · How the report reads
Unchanged
Language tone vs last period
Report language: cautious for a company report — about as upbeat as in Q1 2025.
Weak signal: formal report language, not a call.
3 · What stood out
Figure
The final medical device for dialysis therapy will enter a steadily growing market valued at 2021.
Read between the lines
No major shifts flagged this period.
Tone
How upbeat the language was, compared with other companiesiTone counts positive minus negative finance words, adjusted for length. Executives mostly speak positively, so the labels compare each call with every company's latest call: “typical” is the middle third, “very upbeat” the top tenth, “cautious” the bottom tenth.. Dot: Q1 2026. Ring: Q1 2025.
Cautious for a company report — about as upbeat as in Q1 2025. Periodic reports carry legally required risk wording, so their tone moves little and is a weak signal.
Sentences that drove the tone
“Lack of proceeds from the issuance of Series S shares and restructuring of the loan, or a lack of obtaining bridge financing, while refraining from paying patent fees, will enable the Company to conduct operational activities for a period of...”
“Retail investors may more frequently make decisions to sell shares in response to short-term market changes, which can lead to greater share price volatility. Difficulties in decision-making may occur...”
“Lack of shares may hinder long-term decision-making that requires consensus and stability. Furthermore, a company with a dispersed shareholder base may be more vulnerable to takeover attempts by other entities, as the lack of large...”
Full figures
PLN · PAP Biznes report (2026-05-29)
| Metric | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Operating income | -1.7M | -800.0K | Loss widened |
| Net income | -2.2M | -1.3M | Loss widened |
| P/E | 12-mo loss | 12-mo loss | — |
Topics
Topics are drawn from the full report text, not management commentary.
Most discussed now
- Financial income and expenses resulting from the Company's financial activities include, among others: interest, commissions, gains and…
- Payments of liabilities under finance lease agreements related to operations
- The consequence of a non-approved Payment Request would be a refund of funds for items rejected by the intermediary institution or the…
- In view of the above, the Company is unable to settle more claims than the amount of the actual funding included in the funding agreement.
- The Company makes estimates regarding the financial implications of disclosed contingent assets based on the value of previously recognized…
Faded since Q1 2025
- Fading As of the date of publication of this report, funds from the issuance of series shares have been credited to the Company's accounts.
- Fading The Shareholder's reinvestment took place on July 16, 2024, through the subscription and payment by the Shareholder of 210,600 of the…
- Fading Retail investors may more frequently make decisions to sell shares in response to short-term market changes.
- Fading In the Company's past activities, this risk materialized through the failure to execute the agreement for the sale of rights to PBA-0405…
Latest announcements
Official filings, newest first.
- Powiadomienie o transakcji otrzymane na podstawie art. 19 MAR · ESPI 43/2026
- Half-year report · ESPI periodic
- Podpisanie listu intencyjnego w sprawie przygotowania eksperymentalnego zastosowania terapii genowej w chorobie Huntingtona · ESPI 42/2026
- Komunikat KDPW w sprawie rejestracji akcji serii R i S Spółki · ESPI 41/2026
- Dopuszczenie i warunkowe wprowadzenie do obrotu giełdowego na rynku równoległym akcji zwykłych na okaziciela serii R i S Spółki. Ustalenie daty pierwszego notowania akcji serii R i S Spółki · ESPI 40/2026
- Oświadczenie KDPW w sprawie zawarcia z Emitentem umowy o rejestrację w depozycie papierów wartościowych akcji Spółki serii R i S · ESPI 39/2026
- Zawiadomienie w trybie art. 69 ustawy o ofercie publicznej · ESPI 38/2026
- Zawiadomienie w trybie art. 69 ustawy o ofercie publicznej · ESPI 37/2026